Psilocybin, Cancer Distress and Anxiety: Study Evidence
The two selected randomized reports concern anxiety and depressive symptoms associated with life-threatening cancer. They examine supported research interventions and do not establish that psilocybin treats cancer or all anxiety disorders.
Maintained by Dr. Christopher B. Germann · Primary sources checked .
Original educational annotations. This is a selected comparison, not an exhaustive systematic review, meta-analysis, clinical guideline or personal treatment recommendation. No independent clinical review is claimed.
Reports compared by population, design and endpoint
| Report and population | Design and sample | Endpoint and finding | Limitations |
|---|---|---|---|
| Griffiths et al. · 2016 People with a life-threatening cancer diagnosis and depression or anxiety symptoms PubMed | Randomized double-blind crossover: high versus very low psilocybin dose with psychological support 51 participants | Pre-crossover comparison favored high dose Clinician- and self-rated anxiety and depressive symptoms; randomized comparison before crossover The high-dose condition showed greater symptom reductions. Improvements were also observed at six months after both sequences had received the high dose. | The six-month observations are not a continuing untreated-control comparison. Small, screened sample; expectancy and recognizable drug effects complicate blinding. |
| Ross et al. · 2016 People with cancer-related anxiety and depression PubMed | Randomized double-blind crossover: psilocybin versus niacin, both with psychotherapy 29 participants | Pre-crossover comparisons favored psilocybin Anxiety and depression measures before crossover at seven weeks Pre-crossover comparisons favored psilocybin on the anxiety and depression measures. Later observations suggested persistence after both groups had received psilocybin. | After crossover the study cannot establish a sustained between-group causal effect. A small selected cancer population does not establish efficacy for generalized anxiety disorder. |
Export indexed references · BibTeXRIS
Exports use visible indexed records only. Primary source links remain available when a tracker record is absent or withheld.
What this means for anxiety research
Cancer-related distress can include fear of recurrence, mortality, loss of function and depressive symptoms. That setting differs from a trial recruiting people specifically for generalized anxiety disorder. The population and diagnostic criteria define what can reasonably be inferred.
The randomized evidence is clearest before crossover. Once both sequences receive the active intervention, subsequent improvement is a follow-up observation rather than a continuing comparison against a group that never received it. A durable change and a randomized long-term treatment effect are different claims.
Symptom-rating scales and response thresholds differ. Anxiety, depression, existential distress and quality of life should retain their own measures and assessment times. Avoid combining several outcomes into one success percentage.
Cancer symptoms are not tumour outcomes
These reports address psychological distress. They do not demonstrate tumour shrinkage, longer survival or replacement of oncology care. Trials of psychological support also cannot isolate the contribution of psilocybin from every component of the supported programme.
Compare the depression evidence guide when considering other populations. Use the live cancer literature search to find additional primary reports, follow-ups and reviews.
Safety and applicability
Screening, supervision, psychological support and follow-up are part of these research programmes. Recognizable drug effects can compromise blinding and influence expectations. Small selected samples provide limited information about rare harms and excluded populations.
Assess adverse-event definitions, denominators and observation periods in the original reports. An event occurring during follow-up is not automatically attributed to the intervention. Existing treatment and eligibility decisions require appropriate professional assessment.
Selection and source review
This guide selects two randomized primary cancer-distress reports to support interpretation of a defined research question. Source verification on 9 October 2026 covered report identity, design, population and the outcomes summarized above. No publisher abstracts or instrument questionnaires are reproduced.
Coverage is bounded and may omit relevant or subsequent studies. Consult original articles, their corrections and supplementary methods before citing numerical results. Editorial policy · Data provenance and reuse · Compare selected findings.